Skip to content

Released May 13, 2025, after the close

10-Q filed May 13, 2025, 43 days after period end · 0000950170-25-070380

Q1 2025 · 10-Q
Revenue$12.00K−91.4% vs Q1 2024−76.9% vs Q4 2024
Net Income-$13.87MN/M vs Q1 2024N/M vs Q4 2024
EPS Diluted-$0.25N/M vs Q1 2024no prior Q4 2024 on file
Operating Income-$14,731,000N/M
Operating Cash Flow-$4,002,000N/M
Margins · derived
Operating margin-122758.3%−112771.2 pt vs Q1 2024
Net margin-115550.0%−106500.7 pt vs Q1 2024

What the release said

The release

Same quarter

MetricQ1 2025Q1 2024Q1 2023Q1 2022
Revenue$12.00K$140.00K$223.00K$247.00K
Net Income-$13.87M-$12.67M-$13.30M-$32.80M
EPS Diluted-$0.25-$0.24-$0.25-$1.01

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR